How Hypothyroidism Causes Pseudogout
Hypothyroidism is associated with pseudogout through metabolic alterations that promote calcium pyrophosphate dihydrate (CPPD) crystal deposition in joints, though the exact mechanisms remain incompletely understood and the clinical association is modest.
The Association Between Hypothyroidism and CPPD
The link between hypothyroidism and pseudogout is supported by meta-analysis showing a small but statistically significant association between hypothyroidism and chondrocalcinosis 1. However, this relationship is weaker than other metabolic conditions like hyperparathyroidism, hemochromatosis, or hypomagnesemia that more clearly predispose to CPPD deposition 1.
Proposed Mechanisms
Metabolic Alterations
- Altered cartilage metabolism: Thyroid hormones regulate cartilage matrix composition and turnover. In hypothyroid states, decreased metabolic activity may alter the cartilage microenvironment, favoring CPPD crystal nucleation and growth
- Pyrophosphate metabolism: Changes in inorganic pyrophosphate levels—central to CPP crystal formation—may occur with thyroid dysfunction, though this remains theoretical 2
Associated Metabolic Abnormalities
Hypothyroid patients frequently have concurrent metabolic derangements that independently promote pseudogout:
- Hypocalcemia and hypomagnesemia: These electrolyte abnormalities accounted for nearly 30% of laboratory abnormalities in pseudogout patients 3 and are known to promote CPPD deposition 1
- Elevated parathyroid hormone: Often seen in hypothyroid patients, hyperparathyroidism has strong evidence linking it to chondrocalcinosis 1
Clinical Considerations
Paradoxical Flares with Treatment
A critical caveat: pseudogout attacks can be precipitated by thyroid hormone replacement therapy itself 4. This phenomenon occurs when:
- Rapid correction of hypothyroidism alters the metabolic milieu
- Sudden shifts in calcium and phosphate metabolism trigger crystal shedding from cartilage
- Similar to post-parathyroidectomy pseudogout flares 5
Screening Recommendations
When evaluating CPPD patients, the EULAR guidelines recommend treating identified comorbidities, though whether treating hypothyroidism affects CPPD outcomes remains unclear 2. In patients with pseudogout, consider screening for:
- Thyroid function (TSH, free T4)
- Calcium and magnesium levels
- Parathyroid hormone
- Other metabolic conditions (hemochromatosis, hypophosphatasia)
Management Approach
- Treat the hypothyroidism according to standard guidelines 6, but be aware of potential pseudogout flares during initial treatment
- Manage acute pseudogout attacks with NSAIDs, colchicine, or corticosteroids per EULAR recommendations 2
- Correct electrolyte abnormalities, particularly hypomagnesemia and hypocalcemia
- Monitor for flares when initiating or adjusting thyroid hormone replacement 4
Important Caveats
The evidence linking hypothyroidism to pseudogout is substantially weaker than for other metabolic conditions. A large population-based study found no clinically relevant increased risk of gout (not pseudogout) with hypothyroidism, with an adjusted OR of only 1.12 7. The distinction between gout and pseudogout is important here, as these are different crystal arthropathies.
The association may be confounded by: concurrent metabolic abnormalities (hypomagnesemia, hyperparathyroidism), age-related factors (both conditions increase with age), and autoimmune overlap (autoimmune thyroiditis patients have higher rates of other rheumatologic conditions) 6.
Unlike hemochromatosis, which clearly associates with both chondrocalcinosis and chronic arthropathy, hypothyroidism shows only modest association with crystal deposition and unclear impact on long-term joint outcomes 1.